Acute Lymphoblastic Leukemia News and Research

RSS

Acute lymphoblastic leukemia (ALL) is a cancer of the white blood cells, the cells in the body that normally fight infections. There are two main types of white blood cells-lymphoid cells and myeloid cells. ALL affects lymphoid cells.

UVA research sheds light on how cancer remodels our chromosomes

Cancer remodels the architecture of our chromosomes so the disease can take hold and spread, researchers at the University of Virginia have revealed.

27 Oct 2020

Researchers identify a potential target for small cell lung cancer

The cover for issue 39 of Oncotarget features Figure 4, "Apoptosis assay of NRXN1-targeted ADC at IC50 dose calculated by growth inhibition curves," by Yotsumoto, et al. which reported that the authors identified transmembrane proteins overexpressed specifically in SCLC with little or no expression in normal tissues and decided to focus on the cell adhesion molecule neurexin-1.

1 Oct 2020

NCCN publishes new clinical practice guidelines for pediatric Hodgkin lymphoma

The National Comprehensive Cancer Network today announced the publication of new NCCN Clinical Practice Guidelines in Oncology for Pediatric Hodgkin Lymphoma. Hodgkin lymphoma is one of the most curable forms of pediatric cancer, with long-term survival rates of 90% or higher.

28 Sep 2020

Study identifies hiding place where tumor cells shelter from chemotherapy in childhood leukemia

The stroma of the choroid plexus is one of the locations within the central nervous system (CNS) that serves as a shelter for tumor cells, allowing them to elude chemotherapy and potentially cause subsequent relapses in childhood acute lymphoblastic leukaemia, according to research led by the Complutense University of Madrid.

25 Sep 2020

NCCN's first patient and caregiver resource focused on childhood leukemia

The National Comprehensive Cancer Network today announced the publication of the organization's first patient and caregiver resource focused on a childhood cancer type.

23 Sep 2020

Inherited variation in GATA3 gene is linked to relapse in children with acute lymphoblastic leukemia

Scientists at St. Jude Children's Research Hospital are investigating the inherited genetics of childhood leukemia and how particular gene variations can affect treatment outcomes.

11 Sep 2020

Neil Bell appointed as Chief Development Officer of Avacta Life Sciences

Avacta Group plc, the developer of Affimer biotherapeutics and reagents, is pleased to announce the appointment of Neil Bell as Chief Development Officer of Avacta Life Sciences with immediate effect. Neil will be responsible for late stage pre-clinical and early clinical development of Avacta’s pipeline of pre|CISION pro-drugs and Affimer immunotherapies.

From Avacta Life Sciences Ltd. 13 Aug 2020

FDA approves first CAR T-cell therapy for patients with mantle cell lymphoma

The U.S. Food and Drug Administration granted accelerated approval for brexucabtagene autoleucel (TECARTUS™, formerly KTE-X19) as the first and only CAR T-cell therapy for patients with mantle cell lymphoma (MCL) relapsed or refractory to prior treatments.

28 Jul 2020

Josep Carreras Institute's spin-off aims to develop new immuno-oncological therapeutic tools

The Josep Carreras Leukaemia Research Institute, a public centre pertaining to the Generalitat de Catalunya's (Government of Catalonia) CERCA network, has created the OneChain Immunotherapeutics spin-off, the aim of which is to develop new immuno-oncological therapeutic tools with various preclinical candidates, based on CAR-T technology for different tumors, such as cortical T-cell acute lymphoblastic leukemia (coT-ALL), a rare subtype of leukemia that mainly affects children, and which has a poor prognosis.

20 Jul 2020

Researchers create new tool to identify cancer-causing mutations lurking in 98% of the genome

Gene coding regions constitute 2% of the human genome. St. Jude Children's Research Hospital scientists have developed a computational tool to identify alterations that drive tumor formation in the remaining 98% of the genome.

6 Jul 2020

Researchers receive innovative grants to understand the biological underpinnings of blood cancers

Seeking to ignite the next major breakthroughs to treat blood cancers, The Leukemia & Lymphoma Society (LLS), The Mark Foundation, and The Paul G. Allen Frontiers Group today announced more than $6.75 million awarded to nine of the most exceptional scientists in the field.

1 Jul 2020

Research team solves 40-year old mystery in leukemia treatment

A research team led by the University of Kent and Goethe-University Frankfurt am Main, has solved an almost 40-year old mystery in leukemia therapy and the drug nelarabine.

25 Jun 2020

Researchers investigate nelarabine drug for treating leukemia

Acute lymphoblastic leukemia (ALL) is the most common kind of cancer in children. T-ALL, a subtype that resembles T-lymphocytes, can be treated successfully with the drug nelarabine.

24 Jun 2020

Researchers discover new and improved way to treat poor-prognosis blood cancer

Researchers at Children's Cancer Institute have discovered what could prove a new and improved way to treat the poor-prognosis blood cancer, acute myeloid leukemia or AML.

21 Jun 2020

Drama-based resources help Kingston University nursing students to cope with coronavirus pandemic

A set of drama-based resources to help Kingston University, London nursing students working during the Covid-19 pandemic have been put together through a collaboration with world-leading performing arts school Guildhall School of Music & Drama, London.

21 Jun 2020

Research team generates comprehensive developmental map of human T-cells

Chintan Parekh, MD, of The Saban Research Institute of Children's Hospital Los Angeles, has led a team of investigators that generated a comprehensive roadmap for how T-cells develop in the human thymus.

16 Jun 2020

Damon Runyon Cancer Research Foundation awards $3.2 million to early-career physician-scientists

The Damon Runyon Cancer Research Foundation has named four new Damon Runyon Clinical Investigators.

12 Jun 2020

Study analyzes cancer diagnosis in children with birth defects

Scientific studies suggest that children with birth defects are at increased risk of cancer. However, it has not been assessed whether the type of cancer, the age at which they are diagnosed or the extent of cancer spread at the time of diagnosis, is different for children with birth defects compared to children without birth defects.

29 May 2020

Finding new therapeutic strategies for aggressive T-cell acute lymphoblastic leukemia

Aiming to identify new therapeutic strategies for the aggressive hematological disease T-cell acute lymphoblastic leukemia (T-ALL), Rutgers Cancer Institute of New Jersey resident researcher Daniel Herranz Benito, PhD, along with collaborators from Princeton University, found a new drug that has therapeutic effect against T-ALL by inhibiting SHMT and is complementary to standard-of-care treatment.

12 May 2020

Antioxidant-rich foods can lower risk of infection in children with leukemia

While encouraging children to eat their fruits and veggies is a common refrain for most parents, new research led by a pediatric oncology expert from Roswell Park Comprehensive Cancer Center underscores that diets high in antioxidant-rich foods can have particular benefits for young cancer patients.

2 May 2020